3.93
price up icon5.08%   0.19
 
loading
전일 마감가:
$3.74
열려 있는:
$3.91
하루 거래량:
7,522
Relative Volume:
0.93
시가총액:
$195.13M
수익:
-
순이익/손실:
-
주가수익비율:
-5.3535
EPS:
-0.7341
순현금흐름:
-
1주 성능:
+5.36%
1개월 성능:
+5.08%
6개월 성능:
+0.18%
1년 성능:
+3.42%
1일 변동 폭
Value
$3.91
$3.95
1주일 범위
Value
$3.68
$4.03
52주 변동 폭
Value
$3.35
$6.4229

Genfit Adr Stock (GNFT) Company Profile

Name
명칭
Genfit Adr
Name
전화
-
Name
주소
-
Name
직원
167
Name
트위터
@genfit_pharma
Name
다음 수익 날짜
2024-09-19
Name
최신 SEC 제출 서류
Name
GNFT's Discussions on Twitter

GNFT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
GNFT
Genfit Adr
3.93 195.13M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
487.54 125.43B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
723.80 76.60B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
666.00 39.57B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
277.72 35.33B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
121.26 28.08B 3.30B -501.07M 1.03B -2.1146

Genfit Adr Stock (GNFT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2021-12-20 업그레이드 H.C. Wainwright Neutral → Buy
2020-07-23 업그레이드 Stifel Hold → Buy
2020-06-25 개시 BofA/Merrill Underperform
2020-05-13 다운그레이드 Kepler Buy → Reduce
2020-05-12 다운그레이드 Barclays Overweight → Equal Weight
2020-05-12 다운그레이드 H.C. Wainwright Buy → Neutral
2019-10-29 재확인 B. Riley FBR Buy
2019-06-25 개시 Stifel Hold
2019-04-24 개시 SVB Leerink Outperform
2019-04-22 개시 Barclays Overweight
모두보기

Genfit Adr 주식(GNFT)의 최신 뉴스

pulisher
Jan 30, 2025

GENFIT annonce un accord de financement non dilutif de partage de redevances (royalty financing) et un plan de réduction de sa dette - GlobeNewswire Inc.

Jan 30, 2025
pulisher
Oct 09, 2024

European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN

Oct 09, 2024
pulisher
Oct 09, 2024

European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN

Oct 09, 2024
pulisher
Sep 29, 2024

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - MSN

Sep 29, 2024
pulisher
Sep 26, 2024

European Equities Traded in the US as American Depositary Receipts Move Higher in Tuesday Trading - MSN

Sep 26, 2024
pulisher
Sep 21, 2024

European Equities Traded in the US as American Depositary Receipts Decrease Friday - MSN

Sep 21, 2024
pulisher
Sep 19, 2024

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN

Sep 19, 2024
pulisher
Sep 13, 2024

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN

Sep 13, 2024
pulisher
Sep 08, 2024

European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading - MSN

Sep 08, 2024
pulisher
Sep 06, 2024

European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading - MSN

Sep 06, 2024
pulisher
Sep 06, 2024

European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - MSN

Sep 06, 2024
pulisher
Aug 30, 2024

European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN

Aug 30, 2024
pulisher
Aug 21, 2024

European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading - MSN

Aug 21, 2024
pulisher
Jun 10, 2024

GENFIT: Historic Milestone Achieved with U.S. FDA - GlobeNewswire

Jun 10, 2024
pulisher
Nov 20, 2023

European Equities Traded in the US as American Depositary Receipts Start Week Higher - MSN

Nov 20, 2023
pulisher
Nov 13, 2023

Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine - Ipsen

Nov 13, 2023
pulisher
Jun 30, 2023

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen

Jun 30, 2023
pulisher
Dec 18, 2021

Ipsen und GENFIT schließen im Rahmen einer langfristigen globalen Partnerschaft eine exklusive Lizenzvereinbarung für Elafibranor ab, ein Phase-III-Asset, das für die Behandlung von primärer biliärer Cholangitis geprüft wird - Business Wire

Dec 18, 2021
pulisher
Dec 17, 2021

GENFIT: Ipsen and GENFIT enter into exclusive licensing - GlobeNewswire

Dec 17, 2021
pulisher
Jun 27, 2019

The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO - Yahoo Finance

Jun 27, 2019
pulisher
Apr 09, 2019

The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing - Yahoo Finance

Apr 09, 2019

Genfit Adr (GNFT) 재무 분석

Genfit Adr (GNFT)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$81.27
price up icon 0.40%
$20.50
price down icon 0.58%
$357.02
price up icon 1.02%
$5.6499
price up icon 1.96%
biotechnology ONC
$227.99
price up icon 1.63%
$120.10
price up icon 2.96%
자본화:     |  볼륨(24시간):